By the end of this video, you'll be able to contrast
the Cp time curves of an IV bolus relative
to an oral dose. You will be able to calculate
oral bioavailability and list factors that affected drugs, oral
bioavailability. On the left are IV bolus, Cp time data points. We can sketch a curve
through these points. Absorption is instantaneous and distribution is often complete before the first blood draw. Therefore, always see in
this curve is the drop in Cp from drug clearance via
metabolism and excretion, which gives rise to
observed elimination. To the right, are Cp time
points for an orally dose drug. That's oral drug, PO, that's per OS through the mouth. The curve through these
points starts at Cp a 0 with a rise to a C max, which occurs at t max. Then falls very similarly
to the IV bolus curve. The rising region at the start
is the absorption phase. The falling region is
the elimination phase. The oral curve has an
area under the curve, which is one way to
measure drug exposure, C max, the peak Cp concentration is another way to
describe drug exposure. Here are the two curves
overlaid on the same axes, IV in blue and oral in red. These are the same drug, same doses, different
routes of administration. Because the dose
sizes are identical, you might expect
exposures to be the same. They normally are not, normally exposure
from the oral dose is less than exposure
for the IV dose. The reduction in
oral exposure arises from incomplete oral
drug absorption. Let's now see how we quantify the difference in
exposure and more thoroughly explain why oral
absorption may be incomplete. Here is some key information
from the IV and oral curves, the size of the doses, both 20 mg and AUC
from each dose. These data can be
used to determine another key
pharmacokinetic parameter, oral bioavailability,
F. Bioavailability is reported as a
fractional value from 0 to 1 or as a percentage. Here is the equation
for calculating F. Note that any differences in IV and oral doses are
accommodated in the equation. For our drug based on
the AUC and dose values, the oral bioavailability
is 0.75 or 75%. That's fine. But
where did the other 25% of the oral dose go? Why is absorption not 100%? There are many possible reasons. Perhaps the drug has
poor solubility. Perhaps the drug has low
membrane permeability. Some drugs cross membranes well, but are pumped back into the GI tract by
efflux transporters. Drugs can be metabolized
within the gut lining. This is the intestinal gut or gastric first-pass effect or while passing through the liver, the hepatic first-pass effect in route to the
general circulation. All of these factors can
reduce oral bioavailability. The metabolic stability of any drug is important
to understand, especially for oral drugs. An oral drug with low metabolic
stability will show a large first-pass effect, reduced absorption,
low bioavailability, and low drug exposure
for a patient. Any drug, oral or otherwise with low metabolic stability will show increased
hepatic clearance, which will reduce the
drug's half-life and further decrease drug
exposure for a patient. For these reasons,
drug hunting team spend considerable time understanding the metabolic
stability of hits and leads during the
discovery stage. We have now contrasted IV
and oral Cp time data. We have seen the equation for calculating oral
bioavailability. We have listed selected factors that influence oral
bioavailability.